RBCC: n3D Technology Could Lead to Lab-Grown Implantable Organs

  RBCC: n3D Technology Could Lead to Lab-Grown Implantable Organs

Business Wire

NOKOMIS, Fla. -- February 6, 2013

The magnetic levitation technology that Rainbow Coral Corp. (OTCBB: RBCC)
joint venture partner Nano3D BioSciences (n3D) recently used to grow lifelike
human lung tissue could one day lead to an even more astonishing
breakthrough—lab-grown, implantable human organs.

A recent article by TechNewsDaily described the cell culturing techniques
employed by n3D co-founder Dr. Glauco Souza to levitate and grow layered human
tissues including lung tissue, heart valves and stem cells which show
tremendous promise to advance regenerative medicine.

These breakthroughs are all big steps toward a far-off goal: organ

“Nano3D’s Bio-Assembler technology was recently used to create the first
lab-grown lung tissue with organized layers of cells, and incredibly enough,
that’s only the tip of the iceberg,” said RBCC CEO Patrick Brown. “Dr. Souza
and n3D are truly on the cutting edge of regenerative medicine, and we
couldn’t be more excited to help market it to elite laboratories and
researchers around the globe.”

Rainbow BioSciences, RBCC’s biotech division, signed a joint venture agreement
with n3D last year to help develop and market the Bio-Assembler. The device
utilizes a proprietary process to enable scientists to grow cells in a
three-dimensional environment using nanoparticles that produce magnetic fields
to lift cells from the bottom of petri dishes.

Compared with conventional cell cultures grown on flat surfaces, these three
dimensional cultures form tissues that more closely resemble those found in
the human body. The technique has the potential to drastically reduce the cost
of developing new drugs as well as eliminate the use of animals when testing
the safety of manufactured chemicals—not to mention potentially grow
functional organs from scratch.

For more information on Rainbow BioSciences, please

Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb Co.
(NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT)
and Amgen, Inc. (NASDAQ:AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit our website at [www.RainbowBioSciences.com]. For investment
information and performance data on the Company, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.